Influenza a virus nucleoprotein: A highly conserved multi-functional viral protein as a hot antiviral drug target

Yanmei Hu, Hannah Sneyd, Raphael Dekant, Jun Wang

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Prevention and treatment of influenza virus infection is an ongoing unmet medical need. Each year, thousands of deaths and millions of hospitalizations are attributed to influenza virus infection, which poses a tremendous health and economic burden to the society. Aside from the annual influenza season, influenza viruses also lead to occasional influenza pandemics as a result of emerging or re-emerging influenza strains. Influenza viruses are RNA viruses that exist in quasispecies, meaning that they have a very diverse genetic background. Such a feature creates a grand challenge in devising therapeutic intervention strategies to inhibit influenza virus replication, as a single agent might not be able to inhibit all influenza virus strains. Both classes of currently approved anti-influenza drugs have limitations: the M2 channel blockers amantadine and rimantadine are no longer recommended for use in the U.S. due to predominant drug resistance, and resistance to the neuraminidase inhibitor oseltamivir is continuously on the rise. In pursuing the next generation of antiviral drugs with broad-spectrum activity and higher genetic barrier of drug resistance, the influenza virus nucleoprotein (NP) stands out as a high-profile drug target. This review summarizes recent developments in designing inhibitors targeting influenza NP and their mechanisms of action.

Original languageEnglish (US)
Pages (from-to)2271-2285
Number of pages15
JournalCurrent Topics in Medicinal Chemistry
Volume17
Issue number20
DOIs
StatePublished - Aug 1 2017

Fingerprint

Viral Proteins
Orthomyxoviridae
Antiviral Agents
Human Influenza
Nucleoproteins
Virus Diseases
Drug Resistance
Rimantadine
Oseltamivir
Amantadine
RNA Viruses
Neuraminidase
Pandemics
Virus Replication
Influenza A virus NP protein
Pharmaceutical Preparations
Hospitalization
Economics
Health
Therapeutics

Keywords

  • Antiviral drug resistance
  • Antivirals
  • Influenza virus
  • Nucleoprotein
  • Nucleozin
  • RNA viruses

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Influenza a virus nucleoprotein : A highly conserved multi-functional viral protein as a hot antiviral drug target. / Hu, Yanmei; Sneyd, Hannah; Dekant, Raphael; Wang, Jun.

In: Current Topics in Medicinal Chemistry, Vol. 17, No. 20, 01.08.2017, p. 2271-2285.

Research output: Contribution to journalReview article

@article{f522ede7308d40cc94a2149ab637ea87,
title = "Influenza a virus nucleoprotein: A highly conserved multi-functional viral protein as a hot antiviral drug target",
abstract = "Prevention and treatment of influenza virus infection is an ongoing unmet medical need. Each year, thousands of deaths and millions of hospitalizations are attributed to influenza virus infection, which poses a tremendous health and economic burden to the society. Aside from the annual influenza season, influenza viruses also lead to occasional influenza pandemics as a result of emerging or re-emerging influenza strains. Influenza viruses are RNA viruses that exist in quasispecies, meaning that they have a very diverse genetic background. Such a feature creates a grand challenge in devising therapeutic intervention strategies to inhibit influenza virus replication, as a single agent might not be able to inhibit all influenza virus strains. Both classes of currently approved anti-influenza drugs have limitations: the M2 channel blockers amantadine and rimantadine are no longer recommended for use in the U.S. due to predominant drug resistance, and resistance to the neuraminidase inhibitor oseltamivir is continuously on the rise. In pursuing the next generation of antiviral drugs with broad-spectrum activity and higher genetic barrier of drug resistance, the influenza virus nucleoprotein (NP) stands out as a high-profile drug target. This review summarizes recent developments in designing inhibitors targeting influenza NP and their mechanisms of action.",
keywords = "Antiviral drug resistance, Antivirals, Influenza virus, Nucleoprotein, Nucleozin, RNA viruses",
author = "Yanmei Hu and Hannah Sneyd and Raphael Dekant and Jun Wang",
year = "2017",
month = "8",
day = "1",
doi = "10.2174/1568026617666170224122508",
language = "English (US)",
volume = "17",
pages = "2271--2285",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "20",

}

TY - JOUR

T1 - Influenza a virus nucleoprotein

T2 - A highly conserved multi-functional viral protein as a hot antiviral drug target

AU - Hu, Yanmei

AU - Sneyd, Hannah

AU - Dekant, Raphael

AU - Wang, Jun

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Prevention and treatment of influenza virus infection is an ongoing unmet medical need. Each year, thousands of deaths and millions of hospitalizations are attributed to influenza virus infection, which poses a tremendous health and economic burden to the society. Aside from the annual influenza season, influenza viruses also lead to occasional influenza pandemics as a result of emerging or re-emerging influenza strains. Influenza viruses are RNA viruses that exist in quasispecies, meaning that they have a very diverse genetic background. Such a feature creates a grand challenge in devising therapeutic intervention strategies to inhibit influenza virus replication, as a single agent might not be able to inhibit all influenza virus strains. Both classes of currently approved anti-influenza drugs have limitations: the M2 channel blockers amantadine and rimantadine are no longer recommended for use in the U.S. due to predominant drug resistance, and resistance to the neuraminidase inhibitor oseltamivir is continuously on the rise. In pursuing the next generation of antiviral drugs with broad-spectrum activity and higher genetic barrier of drug resistance, the influenza virus nucleoprotein (NP) stands out as a high-profile drug target. This review summarizes recent developments in designing inhibitors targeting influenza NP and their mechanisms of action.

AB - Prevention and treatment of influenza virus infection is an ongoing unmet medical need. Each year, thousands of deaths and millions of hospitalizations are attributed to influenza virus infection, which poses a tremendous health and economic burden to the society. Aside from the annual influenza season, influenza viruses also lead to occasional influenza pandemics as a result of emerging or re-emerging influenza strains. Influenza viruses are RNA viruses that exist in quasispecies, meaning that they have a very diverse genetic background. Such a feature creates a grand challenge in devising therapeutic intervention strategies to inhibit influenza virus replication, as a single agent might not be able to inhibit all influenza virus strains. Both classes of currently approved anti-influenza drugs have limitations: the M2 channel blockers amantadine and rimantadine are no longer recommended for use in the U.S. due to predominant drug resistance, and resistance to the neuraminidase inhibitor oseltamivir is continuously on the rise. In pursuing the next generation of antiviral drugs with broad-spectrum activity and higher genetic barrier of drug resistance, the influenza virus nucleoprotein (NP) stands out as a high-profile drug target. This review summarizes recent developments in designing inhibitors targeting influenza NP and their mechanisms of action.

KW - Antiviral drug resistance

KW - Antivirals

KW - Influenza virus

KW - Nucleoprotein

KW - Nucleozin

KW - RNA viruses

UR - http://www.scopus.com/inward/record.url?scp=85027358506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027358506&partnerID=8YFLogxK

U2 - 10.2174/1568026617666170224122508

DO - 10.2174/1568026617666170224122508

M3 - Review article

C2 - 28240183

AN - SCOPUS:85027358506

VL - 17

SP - 2271

EP - 2285

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 20

ER -